AR093423A1 - METHOD OF DIAGNOSIS AND STABILIZATION OF CFS / ME SYMPTOMS IN A PATIENT - Google Patents

METHOD OF DIAGNOSIS AND STABILIZATION OF CFS / ME SYMPTOMS IN A PATIENT

Info

Publication number
AR093423A1
AR093423A1 ARP130104118A ARP130104118A AR093423A1 AR 093423 A1 AR093423 A1 AR 093423A1 AR P130104118 A ARP130104118 A AR P130104118A AR P130104118 A ARP130104118 A AR P130104118A AR 093423 A1 AR093423 A1 AR 093423A1
Authority
AR
Argentina
Prior art keywords
candidate patient
sensitive
patient
symptoms
chronic fatigue
Prior art date
Application number
ARP130104118A
Other languages
Spanish (es)
Inventor
R Strayer David
A Carter William
Original Assignee
Hemispherx Biopharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hemispherx Biopharm Inc filed Critical Hemispherx Biopharm Inc
Publication of AR093423A1 publication Critical patent/AR093423A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un método para determinar un paciente candidato sensible que exhiba síntomas asociados con el síndrome de fatiga crónica (CFS/FE) y para estabilizar dichos síntomas del síndrome de fatiga crónica/encefalomielitis miálgica en dicho paciente candidato sensible. El método comprende una primera etapa de (a) determinar si el paciente candidato es sensible al tratamiento, la cual comprende: (a1) medir un valor de ETT en la línea de base proveniente de un paciente candidato que exhiba síntomas asociados con el síndrome de fatiga crónica; y (a2) clasificar un paciente candidato con un valor de ETT en la línea de base mayor a 9 minutos como el paciente candidato sensible. El método comprende una segunda etapa de (b) administrar al paciente candidato sensible Rintatolimod. Por consiguiente, el método estabiliza dichos síntomas del síndrome de fatiga crónica/encefalomielitis miálgica en dicho paciente candidato.A method for determining a sensitive candidate patient exhibiting symptoms associated with chronic fatigue syndrome (CFS / FE) and for stabilizing said symptoms of chronic fatigue syndrome / myelgic encephalomyelitis in said sensitive candidate patient. The method comprises a first step of (a) determining whether the candidate patient is sensitive to treatment, which comprises: (a1) measuring a value of ETT at baseline from a candidate patient exhibiting symptoms associated with the syndrome of chronic fatigue; and (a2) classify a candidate patient with an ETT value at baseline greater than 9 minutes as the sensitive candidate patient. The method comprises a second stage of (b) administering the sensitive candidate patient Rintatolimod. Consequently, the method stabilizes said symptoms of chronic fatigue syndrome / myalgic encephalomyelitis in said candidate patient.

ARP130104118A 2013-07-19 2013-11-08 METHOD OF DIAGNOSIS AND STABILIZATION OF CFS / ME SYMPTOMS IN A PATIENT AR093423A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361856385P 2013-07-19 2013-07-19

Publications (1)

Publication Number Publication Date
AR093423A1 true AR093423A1 (en) 2015-06-03

Family

ID=51293172

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130104118A AR093423A1 (en) 2013-07-19 2013-11-08 METHOD OF DIAGNOSIS AND STABILIZATION OF CFS / ME SYMPTOMS IN A PATIENT

Country Status (2)

Country Link
AR (1) AR093423A1 (en)
WO (1) WO2015010022A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113194963A (en) * 2018-12-13 2021-07-30 Aim免疫科技有限公司 Method for improving exercise tolerance of myalgic encephalomyelitis patient
CN112754435A (en) * 2021-01-20 2021-05-07 山东易听泰医疗技术有限公司 Futian fine stepping experimental instrument

Also Published As

Publication number Publication date
WO2015010022A2 (en) 2015-01-22

Similar Documents

Publication Publication Date Title
CL2015002127A1 (en) Systems and methods for clinical decision support.
CO7240393A2 (en) Compositions comprising a platelet-derived anti-growth factor aptamer (anti-pdgf) and a vascular endothelial growth factor antagonist (vegf)
CL2015002179A1 (en) Optical sets with managed connectivity
CL2016000055A1 (en) Methods to treat or prevent ophthalmic conditions
CR20150200A (en) DERIVATIVES OF EXENDINA-4 AS DUAL AGONISTS OF GLP1 / GLUCACÓN
Pantic Social networking and depression: an emerging issue in behavioral physiology and psychiatric research.
BR112015004878A2 (en) device and method for determining whether predetermined conditions for measuring an individual's first physiological parameter are met, and, clothing to be worn by the individual
CY1122185T1 (en) MEDICINAL USE OF ARTEMISSININ COMPOUNDS AND GEPHYRIN AGENTS
ES2722973T3 (en) Obtaining images in neurological diseases
PE20151873A1 (en) TEST STRIP HOUSING SYSTEM
ECSP13012431A (en) COMBINATION OF THE GLYT1 COMPOUND WITH ANTIPSYCHOTICS
BR112015031698A2 (en) sneaker type sock
MY174894A (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation
CY1123206T1 (en) USE OF THE TELOMERASE INHIBITOR IMETELSTAT FOR THE THERAPEUTIC MANAGEMENT OF MYELODYSPLASTIC SYNDROME
CL2016000392A1 (en) Cortistatin analogues for the treatment of diseases with an inflammatory and / or immune component
CY1124399T1 (en) METHODS OF INCREASING VOLUME IN ASTHMATICS USING BENRALIZUMAB
EA201691860A1 (en) PEPTIDE MEDICINE AS A DRY POWDER
AR100543A1 (en) IMPROVEMENT OF WELL RISING PERFORMANCE
NI201500063A (en) CANCER TREATMENT WITH POMALIDOMIDE IN AN INDIVIDUAL WITH KIDNEY DAMAGE
BR112017011557A2 (en) system for determining immune status or immune cycle, methods for determining immune status and / or immune cycle, for optimizing a physiological response, for improving a physiological response, and for determining an immune state or immune cycle.
AR096327A1 (en) ARTIFICIAL BREATHING DEVICE WITH ABSOLUTE PRESSURE SENSOR AND DIFFERENTIAL PRESSURE SENSOR
BR112017000022A2 (en) Targeted therapeutic nanoparticles and methods of producing and using these particles
CL2016000641A1 (en) A controller for a device for administering a contrast medium comprising a radiological contrast agent in a patient using an injector, and method for determining the optimal volume of a contrast medium comprising a radiological contrast agent to be administered in a patient, before administration.
AR093423A1 (en) METHOD OF DIAGNOSIS AND STABILIZATION OF CFS / ME SYMPTOMS IN A PATIENT
CO2020008863A2 (en) Biomarkers of immune tolerance induced by methotrexate

Legal Events

Date Code Title Description
FB Suspension of granting procedure